US · MTSR
Metsera, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- New York City, NY 10007
- Website
- metsera.com
Price · as of 2025-11-14
$70.50
Market cap 7.5B
Price history
Valuation
| Metric | Value | Upside |
|---|---|---|
| IC Value | — | — |
| P/E | — | |
| P/B | — | |
| P/S | — | |
| EV/EBITDA | — |
Valuation history
Annual price overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | IC | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | |||||
| 2022 | |||||
| 2023 | |||||
| 2024 |
About Metsera, Inc.
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.
- CEO
- Christopher Whitten Bernard
- Employees
- 93
- Beta
- 1.70
Peer comparison
Same-industry comparables, ranked by market cap.
Scroll horizontally for additional metrics. Ticker column stays fixed.
| Basic Info | IC Valuation | Core Valuation | Growth | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | Value | Upside | P/E | P/B | P/S | EV/EBITDA | Sales Growth |
| MTSR | Metsera, Inc. | $70.50 | 7.5B | — | — | — | — | — | — | — |
| ABVX | Abivax S.A. | $99.61 | 7.53B | — | — | -21.33 | 15.13 | — | -21.24 | — |
| ACLX | Arcellx, Inc. | $87.51 | 4.85B | — | — | -28.05 | — | — | -31.38 | -100.00% |
| ARWR | Arrowhead Pharmaceuticals… | $40.31 | 5.57B | — | — | 272.90 | 17.63 | 9.91 | 46.50 | 23258.15% |
| AXSM | Axsome Therapeutics, Inc. | $135.69 | 6.84B | — | — | -42.39 | 87.94 | 12.16 | -45.71 | 65.55% |
| CRSP | CRISPR Therapeutics AG | $56.99 | 5.18B | — | — | -7.54 | 2.28 | 1248.96 | -5.11 | -89.97% |
| CYTK | Cytokinetics, Incorporate… | $59.19 | 7.08B | — | — | -9.18 | -10.93 | 81.88 | -9.82 | 376.56% |
| MRUS | Merus N.V. | $95.18 | 7.22B | — | — | -13.74 | 4.57 | 84.83 | -9.34 | -12.38% |
| NUVL | Nuvalent, Inc. | $92.09 | 6.7B | — | — | -16.73 | 5.70 | — | -548.04 | — |
| PCVX | Vaxcyte, Inc. | $40.32 | 5.23B | — | — | -9.69 | 2.77 | — | -8.22 | — |
| RYTM | Rhythm Pharmaceuticals, I… | $99.47 | 6.61B | — | — | -28.89 | 40.83 | 29.92 | -31.79 | 45.83% |
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $70.50) − 1 = — (IC, example).